Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:CRONNASDAQ:FOMXNYSE:USNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21733,130 shs554,788 shsCRONCronos Group$1.88+1.6%$1.83$1.60▼$3.14$724.57M1.021.38 million shs2.78 million shsFOMXMenlo Therapeutics$2.99$2.99$1.97▼$4.84$184.12M1.66518,350 shsN/AUSNAUSANA Health Sciences$28.24+1.3%$27.62$23.10▼$49.78$532.61M1123,912 shs241,198 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%+33.31%+120.93%CRONCronos Group+1.09%+4.52%+3.35%-1.60%-27.45%FOMXMenlo Therapeutics0.00%0.00%0.00%0.00%0.00%USNAUSANA Health Sciences+1.35%+15.37%-0.01%-19.97%-35.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.3362 of 5 stars3.50.00.04.00.00.01.9CRONCronos Group1.5122 of 5 stars2.04.00.00.02.40.01.3FOMXMenlo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUSNAUSANA Health Sciences4.6243 of 5 stars3.02.00.03.22.51.74.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/A$3.5086.17% UpsideFOMXMenlo Therapeutics 0.00N/AN/AN/AUSNAUSANA Health Sciences 2.00Hold$36.0027.48% UpsideCurrent Analyst Ratings BreakdownLatest FOMX, CRON, CDXC, and USNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.003/5/2025CDXCChromaDexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.80 ➝ $8.102/27/2025USNAUSANA Health SciencesDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $36.002/18/2025USNAUSANA Health SciencesSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$117.62M6.16N/AN/A$2.87 per share0.66FOMXMenlo Therapeutics$3.60M51.15N/AN/A$1.70 per share1.76USNAUSANA Health Sciences$876.24M0.61$3.87 per share7.29$25.99 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%5/6/2025 (Estimated)CRONCronos Group-$73.96M$0.10N/A62.671.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)FOMXMenlo Therapeutics-$74.16M-$1.70N/AN/AN/AN/A-100.58%-81.39%N/AUSNAUSANA Health Sciences$63.79M$1.829.989.770.936.30%10.64%8.48%N/ALatest FOMX, CRON, CDXC, and USNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025Q1 2025USNAUSANA Health Sciences$0.70$0.73+$0.03$0.49$243.08 million$249.54 million2/25/2025Q4 2024USNAUSANA Health Sciences$0.49$0.64+$0.15$0.23$208.82 million$213.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AFOMXMenlo TherapeuticsN/AN/AN/AN/AN/AUSNAUSANA Health SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35CRONCronos GroupN/A24.2423.05FOMXMenlo Therapeutics0.245.725.72USNAUSANA Health SciencesN/A3.933.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%CRONCronos Group8.71%FOMXMenlo Therapeutics46.46%USNAUSANA Health Sciences54.25%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%CRONCronos Group6.90%FOMXMenlo Therapeutics2.95%USNAUSANA Health Sciences0.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableFOMXMenlo Therapeutics8061.58 millionN/AOptionableUSNAUSANA Health Sciences1,90018.86 million19.00 millionOptionableFOMX, CRON, CDXC, and USNA HeadlinesRecent News About These CompaniesUSANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award WinnerApril 28 at 7:27 AM | prnewswire.com17,245 Shares in USANA Health Sciences, Inc. (NYSE:USNA) Acquired by Dark Forest Capital Management LPApril 28 at 5:07 AM | marketbeat.comInvesco Ltd. Raises Holdings in USANA Health Sciences, Inc. (NYSE:USNA)April 28 at 3:33 AM | marketbeat.comResearch Analysts Offer Predictions for USNA FY2025 EarningsApril 27 at 7:36 AM | marketbeat.comSidoti Csr Brokers Increase Earnings Estimates for USNAApril 27 at 2:19 AM | americanbankingnews.comSidoti Csr Cuts Earnings Estimates for USANA Health SciencesApril 25, 2025 | americanbankingnews.comUSANA Health Sciences (NYSE:USNA) Trading Up 16% on Earnings BeatApril 25, 2025 | americanbankingnews.comUSANA Health Sciences (NYSE:USNA) Updates FY 2025 Earnings GuidanceApril 24, 2025 | marketbeat.comUSANA Health Sciences (NYSE:USNA) Posts Earnings Results, Misses Expectations By $0.01 EPSApril 24, 2025 | marketbeat.comUsana Health Sciences Inc (USNA) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...April 24, 2025 | finance.yahoo.comUSANA Health Sciences Sees Sales Growth Amid Earnings DeclineApril 24, 2025 | tipranks.comQ1 2025 USANA Health Sciences Inc Earnings Call TranscriptApril 24, 2025 | gurufocus.comUSANA Philippines Named Among Most Trusted Brands by Reader's DigestApril 23, 2025 | finance.yahoo.comUSANA’s Strong Start in 2025: Earnings Call InsightsApril 23, 2025 | tipranks.comExploring Usana Health Sciences's Earnings ExpectationsApril 23, 2025 | nasdaq.comUSANA Health Sciences posts mixed Q1 results, strong guidanceApril 23, 2025 | investing.comUSANA (NYSE:USNA) Exceeds Q1 Expectations, Full-Year Sales Guidance is OptimisticApril 23, 2025 | msn.comUSANA Health Sciences, Inc. (USNA) Q1 2025 Earnings Call TranscriptApril 23, 2025 | seekingalpha.comUSANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass EstimatesApril 22, 2025 | zacks.comUSANA Health Reports Q1 2025 Financial ResultsApril 22, 2025 | tipranks.comUSANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year OutlookApril 22, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesFOMX, CRON, CDXC, and USNA Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$1.88 +0.03 (+1.62%) As of 04:00 PM EasternCronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Menlo Therapeutics NASDAQ:FOMXFoamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.USANA Health Sciences NYSE:USNA$28.24 +0.35 (+1.25%) As of 03:58 PM EasternUSANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
